skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

2 Total results for product and free and sample content found


Multiple Sclerosis Landscape: Is there a paradigm shift?

Multiple Sclerosis Landscape: Is there a paradigm shift?

The standard of care treatment for multiple sclerosis involves immunomodulatory therapy  to relieve and/or modify symptoms; the vast majority of these are large biologic molecules and are administered via injection. 

Topic multiple-sclerosis

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Ocrevus FDA approval marks watershed moment for MS market

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).

Topic FDA Multiple Sclerosis





電話:+81 (0)3 6273 4260